Maraviroc , a chemokine co-receptor type 5 ( CCR5 ) antagonist , has demonstrated comparable efficacy and safety to efavirenz , each in combination with zidovudine/lamivudine , over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy ( MERIT ) study .